Table 5.
Changes in the LEDD and UPDRS IV score.
| Score | Measures | Preoperative | One Year | Δ Change | % | ^ p |
|---|---|---|---|---|---|---|
| LEDD (mg/dL) | Mean ± SD | 1570.8 ± 662.9 | 721.4 ± 312.4 | −849.4 ± 448.1 | 54.1% | <0.001 * |
| Median (IQR) | 1675.0 (832.5–2175.0) | 691.0 (416.5–975.0) | −800.0 (−1287.5–−360.0) | |||
| Range | 616.0–2500.0 | 300.0–1200.0 | −1514.0–−270.0 | |||
| UPDRS IVa | Mean ± SD | 4.3 ± 2.9 | 1.6 ± 1.5 | −2.8 ± 2.1 | 65.1% | <0.001 * |
| Median (IQR) | 5.0 (1.3–7.0) | 1.3 (0.3–2.0) | −3.0 (−4.9–−1.0) | |||
| Range | 0.0–8.0 | 0.0–5.0 | −6.0–1.0 | |||
| UPDRS IVb | Mean ± SD | 3.5 ± 1.8 | 1.8 ± 1.0 | −1.7 ± 1.1 | 48.6% | <0.001 * |
| Median (IQR) | 4.0 (2.3–5.0) | 2.0 (1.0–2.9) | −2.0 (−2.0–−1.0) | |||
| Range | 0.0–6.0 | 0.0–3.0 | −4.0–0.0 |
Total = 20, Δ Change from before to after (negative values indicate a reduction, which is an indicator of improvement); LEDD levodopa equivalent daily dose; p probability (p-value); SD standard deviation; UPDRS Unified Parkinson’s Disease Rating Scale; % percentage of change; ^ Wilcoxon Signed Ranks Test; * Significant.